Foldamers rescue synucleinopathy phenotypes in multiple in vitro and in vivo models - PubMed
4 hours ago
- #synucleinopathies
- #Parkinson's disease
- #foldamers
- Foldamer SK-129 inhibits α-synuclein aggregation, a key feature of synucleinopathies like Parkinson's disease and Lewy body dementia.
- SK-129 binds neurotoxic α-synuclein oligomers with high affinity, crosses the blood-brain barrier, and shows favorable pharmaceutical properties in mice.
- Treatment with SK-129 rescues pathology in cellular, C. elegans, and human iPSC-derived neuron models, and improves survival in a mouse model.
- SK-129 inhibits α-synuclein aggregation mediated by exosomes from PD patients and prevents α-synuclein-tau co-aggregation linked to Lewy body dementia.